FLGT — Fulgent Genetics, Inc.

Fulgent Genetics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $71.1 million, down 3.2% year-over-year and 14.6% quarter-over-quarter, primarily due to reduced sales from a large customer transitioning testing in-house.
• Gross Margin: GAAP gross margin at 30.2%; non-GAAP gross margin at 32.3%, reflecting fixed costs amid lower revenue.
• Operating Expenses: GAAP operating expenses decreased to $56.1 million from $68.8 million in the prior quarter, largely due to a one-time expense in the previous quarter.
• Net Loss: GAAP loss of $24.8 million, or $0.08 per share; adjusted EBITDA loss of approximately $15.2 million.
• Cash Position: Ended the quarter with approximately $604.7 million in cash and equivalents, down $100.8 million due to acquisitions and stock repurchases.

2. Strategic Updates and Business Highlights

• Acquisitions: Completed acquisitions of Bako Diagnostics and StrataDx, contributing $2.6 million to Q1 revenue. The focus is now on integration and cross-training sales teams.
• Laboratory Services: Continued investment in AI and digital pathology, with the launch of new tools to enhance diagnostic accuracy and efficiency.
• Therapeutic Development: Progress on clinical candidates FID-007 and FID-022, with FID-007 selected for presentation at ASCO, indicating positive early efficacy data.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated total revenue guidance of $350 million, representing an 8.5% year-over-year growth.
• Segment Revenue Estimates: Precision Diagnostics at approximately $168 million, Anatomic Pathology at $162 million, and Biopharma Services at $20 million.
• Gross Margin Expectations: Non-GAAP gross margins expected to improve to approximately 39% for the year, with further improvements anticipated by year-end.

4. Bad News, Challenges, or Points of Concern

• Customer Concentration Risk: Significant revenue decline from the largest customer, which is expected to continue impacting Q2 before stabilizing in the second half of the year.
• Gross Margin Decline: Lower-than-expected gross margins due to reduced revenue and operational challenges, including weather-related lab shutdowns and claims processing delays.
• Stock Repurchase Impact: Adjusted non-GAAP EPS guidance reflects a decrease of $0.14 due to share repurchases, potentially affecting perceived profitability.

5. Notable Q&A Insights

• Underlying Growth: Excluding the impact of the largest customer, the underlying growth in Precision Diagnostics is in the teens.
• Q2 Expectations: Anticipated higher revenue in Q2, benefiting from a full quarter of contributions from the recent acquisitions.
• Product Development: Excitement around advancements in whole genome and whole exome testing, particularly in rare diseases and pharmacogenomics.
• Commercialization Strategy: Plans for FID-007 include seeking partnerships but also maintaining the option to self-fund clinical trials to strengthen negotiation positions.

Overall, Fulgent Genetics is navigating challenges related to customer transitions and revenue declines while positioning itself for growth through strategic acquisitions and product development in the diagnostics and therapeutic sectors.